Federico Pio Fabrizio: An Up-to-Date Overview of the Co-Mutation Landscape in NSCLC
Federico Pio Fabrizio, Associate Professor in Molecular Biology at Kore University of Enna, shared an article he co-authored with colleagues, published in Cancers:
“A recent review article published in Cancers (MDPI), developed in collaboration with Prof. Filippo de Marinis and Dr. Ilaria Attili from the European Institute of Oncology (IEO):
The paper provides an up-to-date overview of the co-mutation landscape in non-small cell lung cancer (NSCLC), highlighting its prognostic, therapeutic, and clinical implications. The review emphasizes the need for integrated, biomarker-driven approaches to improve the management of advanced-stage NSCLC and overcome the limitations of targeted therapies.
The discovery of oncogenic drivers such as EGFR, ALK, and KRAS has enabled the development of targeted treatments that have significantly improved patient survival and quality of life. However, clinical reality is often more complex.
Co-mutations in genes like TP53, STK11, KEAP1, PIK3CA, RB1, and others recently identified can influence therapeutic response, disease progression, and the development of both primary and acquired resistance. These co-alterations contribute to the molecular heterogeneity of NSCLC and represent a growing challenge in precision oncology.”
Title: Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List
Authors: Ilaria Attili, Federico Pio Fabrizio, Filippo de Marinis
You can read the Full Article in Cancers.
More posts featuring Federico Pio Fabrizio.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023